Subtopic Deep Dive
Tacrolimus Pharmacogenetics
Research Guide
What is Tacrolimus Pharmacogenetics?
Tacrolimus pharmacogenetics studies genetic polymorphisms in CYP3A5, ABCB1, and CYP3A4 genes that influence tacrolimus metabolism, dosing requirements, and clinical outcomes in renal transplant recipients.
Research focuses on variants like CYP3A5*1 and CYP3A4 intron 6 polymorphism affecting tacrolimus pharmacokinetics and time to target concentrations. Over 1,600 citations across key papers document dosing algorithms incorporating genotypes. Studies span pediatric heart transplants and adult kidney transplants, emphasizing personalized immunosuppression.
Why It Matters
Tacrolimus pharmacogenetics reduces rejection risks and toxicity by enabling genotype-guided dosing in kidney transplants, as shown in MacPhee et al. (2004) where CYP3A5 expressers needed twofold higher doses. Passey et al. (2011) developed dosing equations using CYP3A5 variants and clinical factors, improving therapeutic range achievement and graft survival. Elens et al. (2011) identified CYP3A4 intron 6 impacts on pharmacokinetics, supporting precision medicine to minimize adverse effects in 20-30% of recipients with suboptimal levels.
Key Research Challenges
Interindividual Dose Variability
CYP3A5*1 carriers require 2-4 fold higher tacrolimus doses to reach target troughs, delaying therapeutic levels post-transplant (MacPhee et al., 2004; Zheng et al., 2003). This increases rejection risk in early weeks. Algorithms must integrate multiple factors beyond genotype.
Limited Prospective Validation
Most evidence from retrospective studies like Passey et al. (2011) dosing equations lacks large randomized trials confirming reduced toxicity or rejection. Brunet et al. (2019) consensus calls for validation of pharmacogenetic-guided TDM. Ethnic differences in allele frequencies complicate generalizability.
Gene-Environment Interactions
Gut microbiota influences tacrolimus dosing alongside genetics (Lee et al., 2015), but models rarely incorporate microbiome data. CYP3A4 polymorphisms add variability (Elens et al., 2011). Comprehensive models need multi-omics integration.
Essential Papers
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Mercè Brunet, Teun van Gelder, Anders Åsberg et al. · 2019 · Therapeutic Drug Monitoring · 601 citations
Abstract: Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Associati...
Cyclosporine: A Review
Dustin Tedesco, Lukas Haragsim · 2012 · Journal of Transplantation · 282 citations
The discovery and use of cyclosporine since its inception into clinical use in the late 1970s has played a major role in the advancement of transplant medicine. While it has improved rates of acute...
Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms
Hongxia Zheng, Steven Webber, Adriana Zeevi et al. · 2003 · American Journal of Transplantation · 265 citations
Tacrolimus is a substrate for P-glycoprotein (P-gp) and cytochrome (CYP) P4503A. P-gp is encoded by the multiple drug resistance gene MDR1 and CYP3A is the major enzyme responsible for tacrolimus m...
The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation
Iain MacPhee, Salim Fredericks, Tracy W Tai et al. · 2004 · American Journal of Transplantation · 257 citations
Previously, we reported that, at 3 months after renal transplantation, individuals with CYP3AP1 genotype CYP3AP1*1 (linked to CYP3A5*1 and strongly associated with expression of CYP3A5) required tw...
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
Laure Elens, Rachida Bouamar, Dennis A. Hesselink et al. · 2011 · Clinical Chemistry · 239 citations
BACKGROUND Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity. Tac pharmacokinetics varies between individuals and thus complicates its use in preventing rejection after kidn...
Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation
John R. Lee, Thangamani Muthukumar, Darshana M. Dadhania et al. · 2015 · PLoS ONE · 199 citations
Tacrolimus dosing to establish therapeutic levels in recipients of organ transplants is a challenging task because of much interpatient and intrapatient variability in drug absorption, metabolism, ...
Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation–Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation
Michael Mengel, Alexandre Loupy, Mark Haas et al. · 2020 · American Journal of Transplantation · 196 citations
This meeting report from the XV Banff conference describes the creation of a multiorgan transplant gene panel by the Banff Molecular Diagnostics Working Group (MDWG). This Banff Human Organ Transpl...
Reading Guide
Foundational Papers
Start with Zheng et al. (2003) for CYP3A5/MDR1 basics in dosing, then MacPhee et al. (2004) for kidney transplant time-to-target, and Passey et al. (2011) for clinical dosing equations.
Recent Advances
Study Brunet et al. (2019) consensus on personalized TDM and Elens et al. (2011) for CYP3A4 intron 6 polymorphism effects.
Core Methods
Core techniques include genotyping (CYP3A5*1 detection), population PK modeling, and regression-based dosing equations with hematocrit/age/genotype predictors.
How PapersFlow Helps You Research Tacrolimus Pharmacogenetics
Discover & Search
Research Agent uses searchPapers with 'CYP3A5 tacrolimus kidney transplant' to retrieve 50+ papers including MacPhee et al. (2004), then citationGraph reveals 257 forward citations linking to Brunet et al. (2019) consensus. findSimilarPapers on Zheng et al. (2003) uncovers pediatric extensions; exaSearch scans 250M+ OpenAlex papers for unpublished preprints on ABCB1 variants.
Analyze & Verify
Analysis Agent applies readPaperContent to extract CYP3A5*1 dose ratios from Zheng et al. (2003), then verifyResponse with CoVe cross-checks against Passey et al. (2011) equations. runPythonAnalysis simulates dosing models using NumPy/pandas on genotype data for statistical verification of 2-fold differences. GRADE grading scores Elens et al. (2011) as high evidence for CYP3A4 effects.
Synthesize & Write
Synthesis Agent detects gaps in prospective trials via contradiction flagging between MacPhee et al. (2004) and Brunet et al. (2019), generating exportMermaid diagrams of genotype-dose relationships. Writing Agent uses latexEditText to draft methods sections, latexSyncCitations for 20+ references, and latexCompile for publication-ready reviews on personalized dosing.
Use Cases
"Run stats on CYP3A5 variant dose requirements from key tacrolimus papers"
Research Agent → searchPapers('CYP3A5 tacrolimus dosing') → Analysis Agent → readPaperContent(Zheng 2003, MacPhee 2004) → runPythonAnalysis(pandas meta-analysis of dose ratios) → researcher gets CSV of effect sizes and p-values.
"Write LaTeX review of tacrolimus pharmacogenetics dosing algorithms"
Synthesis Agent → gap detection(Passey 2011 algorithms) → Writing Agent → latexEditText(intro) → latexSyncCitations(10 papers) → latexCompile → researcher gets PDF with figures and bibliography.
"Find GitHub code for tacrolimus dosing models from papers"
Research Agent → searchPapers('tacrolimus dosing equation') → paperExtractUrls(Passey 2011) → paperFindGithubRepo → githubRepoInspect → researcher gets validated Python scripts for genotype-based predictions.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(100 tacrolimus pharmacogenetics papers) → citationGraph → GRADE all → structured report on CYP3A5 evidence. DeepScan applies 7-step analysis with CoVe checkpoints to verify Elens et al. (2011) CYP3A4 claims against 20 similar papers. Theorizer generates hypotheses on microbiota-genotype interactions from Lee et al. (2015) and Zheng et al. (2003).
Frequently Asked Questions
What is tacrolimus pharmacogenetics?
It examines CYP3A5*1, ABCB1, and CYP3A4 polymorphisms affecting tacrolimus metabolism and dosing in transplant patients (Zheng et al., 2003; Elens et al., 2011).
What are main methods in this field?
Genotyping for CYP3A5*3/*1, pharmacokinetic modeling, and dosing equations incorporating variants and clinical factors (Passey et al., 2011; MacPhee et al., 2004).
What are key papers?
Zheng et al. (2003, 265 citations) links CYP3A5/MDR1 to pediatric dosing; MacPhee et al. (2004, 257 citations) shows time-to-target effects; Brunet et al. (2019, 601 citations) provides TDM consensus.
What are open problems?
Prospective trials validating dosing algorithms, integrating microbiota data (Lee et al., 2015), and multi-ethnic models remain unsolved.
Research Renal Transplantation Outcomes and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Tacrolimus Pharmacogenetics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers